URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
UroGen Pharma Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$34.15−0.41 (-1.19%)
Close on Oct 19, 2026
- Market cap
- $1.72B
- P/E (TTM)
- –
- Dividend yield
- –
UroGen Pharma Ltd. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zusduri [Member] | $95.47M | $45.05M | $15.80M | $1.78M | $0 | – | $0 | – | – | – | – | – | 50.6% | – |
| Jelmyto [Member] | $93.26M | $95.45M | $93.99M | $94.74M | $94.24M | $91.87M | $90.40M | $89.36M | $85.01M | $84.30M | $82.71M | $77.28M | 49.4% | -1.0% |
By region
From the segment and revenue-disaggregation notes of UroGen Pharma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.